Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

aDepartments of Surgery, New York University, New York, NY, USA bDepartment of Medicine, New York University, New York, NY, USA ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the ... manufacturing standardization, and formal dosing protocols. Compounding pharmacies serve important therapeutic ...

aThe First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China bLuoyang Key Laboratory of Clinical Multiomics and Translational ...

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-t ...

WHYY thanks our sponsors — become a WHYY sponsor Glucagon-like peptide-1 agonists ... GLP-1 exposure cases include calls made by people with a suspected poisoning or by people who are experiencing any ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.